User menu

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [I-123]-FP-CIT SPECT imaging: The [I-123]-FP-CIT study group

Bibliographic reference Benamer, HTS ; Patterson, J ; Grosset, DG ; Booij, J ; de Bruin, K ; et. al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [I-123]-FP-CIT SPECT imaging: The [I-123]-FP-CIT study group. In: Movement Disorders, Vol. 15, no. 3, p. 503-510 (2000)
Permanent URL
  1. Critchley E., Clinical manifestations of essential tremor, 10.1136/jnnp.35.3.365
  2. Larsen T. Andreo, Calne Donald B., Essential Tremor : , 10.1097/00002826-198309000-00002
  3. Marshall J., OBSERVATIONS ON ESSENTIAL TREMOR, 10.1136/jnnp.25.2.122
  4. Essential tremor. An epidemiological, clinical, and genetic study [thesis]. Turku, Finland: University of Turku, 1978.
  5. Brooks D. J., Playford E. D., Ibanez V., Sawle G. V., Thompson P. D., Findley L. J., Marsden C. D., Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18F-dopa PET study, 10.1212/wnl.42.8.1554
  6. Quinn N., Fortnightly Review: Parkinsonism--recognition and differential diagnosis, 10.1136/bmj.310.6977.447
  7. Brooks David J., Functional imaging in relation to parkinsonian syndromes, 10.1016/0022-510x(93)90061-3
  8. Amara Susan G., Kuhar Michael J., Neurotransmitter Transporters: Recent Progress, 10.1146/
  9. Jaber Mohamed, Jones Sara, Giros Bruno, Caron Marc G, The dopamine transporter: A crucial component regulating dopamine transmission, 10.1002/mds.870120502
  10. Kaufman Marc J., Madras Bertha K., Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum, 10.1002/syn.890090107
  11. Niznik Hyman B., Fogel Evan F., Fassos Frank F., Seeman Philip, The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus, 10.1111/j.1471-4159.1991.tb02580.x
  12. Rajput A. H., Rozdilsky B., Ang L., Rajput A., Clinicopathologic observations in essential tremor: Report of six cases, 10.1212/wnl.41.9.1422
  13. Asenbaum S., Pirker W., Angelberger P., Bencsits G., Pruckmayer M., Brücke T., [ 123 I]β-CIT and SPECT in essential tremor and Parkinson's disease, 10.1007/s007020050124
  14. Laruelle Marc, Wallace Elizabeth, Seibyl John P., Baldwin Ronald M., Zea-Ponce Yolanda, Zoghbi Sami S., Neumeyer John L., Charney Dennis S., Hoffer Paul B., Innis Robert B., Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects, 10.1038/jcbfm.1994.131
  15. Booij Jan, Andringa Gerda, Rijks Leonie J.M., Vermeulen R. Jeroen, De Bruin Kora, Boer Gerard J., Janssen Anton G.M., Van Royen Eric A., [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys, 10.1002/(sici)1098-2396(199711)27:3<183::aid-syn4>;2-9
  16. Booij Jan, Busemann Sokole Ellinor, Stabin Michael G., Janssen Anton G. M., de Bruin Kora, van Royen Eric A., Human biodistribution and dosimetry of [ 123 I]FP-CIT: a potent radioligand for imaging of dopamine transporters, 10.1007/s002590050190
  17. Booij J, Tissingh G, Boer G J, Speelman J D, Stoof J C, Janssen A G, Wolters E C, van Royen E A, [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease., 10.1136/jnnp.62.2.133
  18. Booij J., Tissingh G., Winogrodzka A., Boer G. J., Stoof J. C., Wolters E. C., van Royen E. A., Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease, 10.1007/bf01728311
  19. Tissingh, J Nucl Med, 37, 1143 (1998)
  20. Booij, J Nucl Med, 39, 1879 (1998)
  21. Gibb W R, Lees A J, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease., 10.1136/jnnp.51.6.745
  22. Definitions and behavioural classifications. In: eds. Handbook of Tremor Disorders. New York, NY: Marcel Dekker, 1995:1-5.
  23. members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: eds. Recent Developments in Parkinson's Disease. Florham Park; NJ: Macmillan Healthcare Information, 1987:153-164.
  24. Hughes A.J, Lees A.J, Stern G.M, Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes, 10.1016/0140-6736(90)91531-e
  25. D'Costa D F, Abbott R J, Pye I F, Millac P A, The apomorphine test in parkinsonian syndromes., 10.1136/jnnp.54.10.870
  26. Hughes A. J., Lees A. J., Stern G. M., Challenge tests to predict the dopaminergic response in untreated Parkinson's disease, 10.1212/wnl.41.11.1723
  27. Gasser T., Schwarz J., Arnold G., Trenkwalder C., Oertel W. H., Apomorphine Test for Dopaminergic Responsiveness in Patients With Previously Untreated Parkinson's Disease, 10.1001/archneur.1992.00530350045017
  28. Neurology, 46, 147 (1996)
  29. Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin R. C., Goetz C. G., Golbe L. I., Grafman J., Growdon J. H., Hallett M., Jankovic J., Quinn N. P., Tolosa E., Zee D. S., Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop, 10.1212/wnl.47.1.1
  30. Hoehn M. M., Yahr M. D., Parkinsonism: onset, progression, and mortality, 10.1212/wnl.17.5.427
  31. et al. Development of a useful [123I]-FP-CIT SPECT protocol to demonstrate the dopaminergic deficit in patients with Parkinson's disease in routine clinical studies. In: Imaging of dopamine transporters in Parkinson's disease with SPECT, chapter 5. PhD Thesis, University of Amsterdam 1998:69-91.
  32. Abi-Dargham, J Nucl Med, 37, 1129 (1996)
  33. An Atlas of the Human Brain for Computed Tomography. Stuttgart: Gustau Fister Verlag, 1978.
  34. Seibyl, J Nucl Med, 39, 1500 (1998)
  35. Hughes A J, Daniel S E, Kilford L, Lees A J, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases., 10.1136/jnnp.55.3.181
  36. Hughes A. J., Ben-Shlomo Y., Daniel S. E., Lees A. J., What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study, 10.1212/wnl.42.6.1142
  37. Research diagnostic criteria for Parkinson's disease. In: eds. Advances in Neurology. New York, NY: Raven Press, 1990;53:245-249.
  38. Brücke T., Asenbaum S., Pirker W., Djamshidian S., Wenger S., Wöber Ch., Müller Ch., Podreka I., Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT, Advances in Research on Neurodegeneration (1997) ISBN:9783211828984 p.9-24, 10.1007/978-3-7091-6842-4_2
  39. Messa C., Volonté M. A., Fazio F., Zito F., Carpinelli A., d'Amico A., Rizzo G., Moresco R. M., Paulesu E., Franceschi M., Lucignani G., Differential distribution of striatal [ 123 I]β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography, 10.1007/s002590050295
  40. Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. J., Differing patterns of striatal18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy, 10.1002/ana.410280412
  41. Burn D J, Sawle G V, Brooks D J, Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data., 10.1136/jnnp.57.3.278
  42. Antonini A, Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease, 10.1093/brain/120.12.2187